Dr. Mohammad Madjid, MD

Dr. Madjid practices at UCLA Medical Plaza in Los Angeles, California.

Dr. Madjid's NPI, 1083868145, was assigned on November 15, 2008. Dr. Madjid graduated from Tehran University of Medical Sciences School of Medicine in 1997. Dr. Madjid holds California license A151218.

Dr. Madjid's primary practice is UCLA Medical Plaza, at 5767 W Century Blvd, Los Angeles, CA 90045 in Los Angeles County. The practice phone is (310) 794-1276.

Dr. Madjid's primary practice is UCLA Medical Plaza in Los Angeles, California. Dr. Madjid is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Madjid to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Madjid practices, 5 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Madjid's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Madjid is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Madjid's licenses on file in 2 states: California and Texas.

CMS data shows 4,558 Medicare services from Dr. Madjid across 33 procedure codes in 2024, for 1,296 Medicare patients. Medicare paid $283,800 for them.

CMS counts 1,296 Medicare patients who saw Dr. Madjid in 2024. The largest group is 75 to 84, with 493 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Madjid's median patient age at 66, with 53% women.

In 2024, Dr. Madjid wrote 2,790 Medicare Part D claims for 401 patients. 84% of them were for generic drugs. CMS names the drug for 2,593 of them, across 43 drugs with 11 or more claims each, at $416,371 in total drug cost. In 2023, CMS named 1,510 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Madjid for performance year 2024, reported as part of a group. Dr. Madjid accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Madjid as offering telehealth.

Coronary angioplasty and stenting: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 48 papers to Dr. Madjid, published from 2005 to 2024. 2019 was the busiest year, with 6. The most frequent topics are COVID-19, SARS-CoV-2 and Cardiovascular Diseases. Dr. Madjid has published most often in Tex Heart Inst J. Dr. Madjid's most frequent co-authors are Daniel M. Musher, MD, Richard W. Smalling, MD and Geoffrey Douglas Barnes, MD.

Dmand AI links Dr. Madjid to 1 clinical trial. Conditions studied include Common Cold and Picornaviridae Infections.

CMS Open Payments shows 242 general payments to Dr. Madjid from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 51% of the total. Sanofi Pasteur Inc. paid the most, $134,509.

Dr. Madjid graduated from Tehran University of Medical Sciences School of Medicine in 1997. Dr. Madjid is a member of ACC.

Dr. Madjid is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.